BioSpace News Archive

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease.

Belharra Therapeutics, Inc. is a privately held drug discovery company whose novel photoaffinity-based chemoproteomics platform is disrupting the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharra’s proprietary noncovalent drug discovery engine is uniquely capable of identifying novel starting points for transformative medicines to address previously impossible-to-treat diseases and conditions. 

Bonum Therapeutics is focused on a proven technology that utilizes regulation to create targeted, highly active, and less toxic medicines.

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies.

Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed. Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments.

Evolve Biologics is an innovative developer of plasma-derived therapeutics. We are a new kind of biologics company founded for a clear purpose: bringing critical therapeutics to the people who need them.

NemaLife’s mission is to accelerate and de-risk R&D for companies in the food, nutraceutical, microbiome and pharma industries.

Our mission is to improve the health, vitality, and longevity of human beings through bioengineering. At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight.

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs.

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO.